New Class of Cholesterol-Lowering Drugs Shows Promise

Taking a different path, PCSK9 Inhibitors reduce LDL cholesterol in statin-intolerant patients.

For patients who are unable to reap cholesterol-lowering benefits from the drugs known as statins due to intolerable side effects, technology may soon offer an alternative and effective treatment. While statins, including the most commonly used atorvastatin (Lipitor), simvastatin (Zocor) and rosuvastatin (Crestor) are the first line of treatment for reducing levels of the artery-clogging fatty deposits that increase bad cholesterol (LDL) levels, a new class of drugs may provide an unmet need in cholesterol-lowering alternatives, according to Michael Rocco, MD, Medical Director of Cardiac Rehabilitation and Stress Testing and staff cardiologist at Cleveland Clinic.
To continue reading this article or issue you must be a paid subscriber. Sign in

Subscribe to Heart Advisor

Get the next year of Heart Advisor for just $20. And access all of our online content - over 2,000 articles - free of charge.
Subscribe today and save 38%. It's like getting 5 months FREE!
Already Subscribed?
Click Here to Sign In | Forgot your password? | Activate Web Access